Search Results 981-990 of 2490 for hemoglobin

1. Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma - Mayo Clinic

   Hemoglobin (Hb) ≥ 8 g/dL;; Platelets (PLT) ≥ 75 × 10^9 /L or ≥ 50 × 10^9 /L in case of documented bone marrow involvement (> 50% or tumor cells), without ...

2. CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin - Mayo Clinic

   Hemoglobin > 9 g/dl; Absolute neutrophil count ≥ 1,500/mcL; Platelets ≥ 100,000/mcL; Total bilirubin < 1.5 X ULN; AST(SGOT)/ALT(SGPT) ≤3 X ULN (including ...

3. Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations - Mayo Clinic

   Hemoglobin ≥ 8.0 g/dL. Serum albumin ≥ 3.5 g/dL. Subjects with tumors potentially highly sensitive to tipifarnib (HRAS mutant VAF ≥35%) may be enrolled ...

4. A Study Of Obesity And Inflammation Impact Immunotherapy For Renal Cancer - Mayo Clinic

   Demonstrate adequate organ function: leukocytes >1,000/mm3; an absolute neutrophil count ≥1,000/mL; platelets ≥70,000/mL; hemoglobin ≥8 g/dL; total ...

5. Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors - Mayo Clinic

   s Glycemic Target Goals is hemoglobin A1C < 7%). Anemia (hematocrit < 28%). Currently using select CYP2D6 inhibitor or inducer medications. Inability to ...

6. P1101 in Treating Patients With Myelofibrosis - Mayo Clinic

   Hemoglobin < 10 g/dL. Confirmed diagnosis of myelofibrosis (primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia or polycythemia ...

7. A Study of Macitentan in Pulmonary Hypertension After Left Ventricular Assist Device Implantation - Mayo Clinic

   Hemoglobin < 8.5 g/dL at randomization; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) at ...

8. A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia - Mayo Clinic

   Hemoglobin ≥ 8 g/dL;; Total bilirubin ≤ 1.5 mg/dL or < 2 mg/dL if attributable to hepatic infiltration by neoplastic disease;; AST/ALT ≤ 2.5 ...

9. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ - Mayo Clinic

   Bone marrow: platelets ≥75 x 109/L, absolute neutrophil count (ANC) ≥1.5 x 109/L, hemoglobin ≥10 g/dL. (Platelets ≥50 x 109/L, ANC ≥1.0 x 109/L, hemoglobin ...

10. First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors - Mayo Clinic

    Hemoglobin ≥ 9 g/dL. Have no clinically significant abnormalities on urinalysis. Have acceptable coagulation status: Prothrombin time (PT) within 1.5 ...